SERPINA1 and alpha 1-antitrypsin deficiency: Clinically, patients with AATD have an increased risk of developing emphysema, cirrhosis, panniculitis and vasculitis, as well as a greater susceptibility to viral infection and persistent infections.1 Currently, the only condition-specific treatment for AATD-associated diseases is weekly intravenous (IV) augmentation treatment with human AAT (AAT therapy), at a typical dose of 60 mg/kg.